Results of a phase 1 b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients? 65 years ineligible for standard induction therapy.

被引：28

作者：

Pollyea, Daniel Aaron

Dinardo, Courtney Denton

Thirman, Michael J.

Letai, Anthony

Wei, Andrew H.

Jonas, Brian Andrew

Arellano, Martha Lucia

Frattini, Mark G.

Kantarjian, Hagop M.

Chyla, Brenda

Zhu, Ming

Potluri, Jalaja

Humerickhouse, Rod

Mabry, Mack H.

Konopleva, Marina

Pratz, Keith William

机构：

[1] Univ Colorado, Sch Med, Aurora, CO USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Alfred Hosp, Melbourne, Australia

[6] Monash Univ, Melbourne, Australia

[7] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[8] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[11] AbbVie Inc, N Chicago, IL USA

[12] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7009

引用

页数：4

共 50 条

[1] RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS ≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
Pollyea, D. A.
Di Nardo, C.
Thirman, M.
Letai, A.
Wei, A.
Jonas, B. A.
Arellano, M.
Frattini, M.
Kantarjian, H.
Chyla, B.
Zhu, M.
Potluri, J.
Humerickhouse, R.
Mabry, M.
Konopleva, M.
Pratz, K.
HAEMATOLOGICA, 2016, 101 : 44 - 44
[2] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Yamamoto, Kazuhito
Shinagawa, Atsushi
DiNardo, Courtney D.
Pratz, Keith W.
Ishizawa, Kenichi
Miyamoto, Toshihiro
Komatsu, Norio
Nakashima, Yasuhiro
Yoshida, Chikashi
Fukuhara, Noriko
Usuki, Kensuke
Yamauchi, Takahiro
Asada, Noboru
Asou, Norio
Choi, Ilseung
Miyazaki, Yasushi
Honda, Hideyuki
Okubo, Sumiko
Kurokawa, Misaki
Zhou, Ying
Zha, Jiuhong
Potluri, Jalaja
Matsumura, Itaru
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
[3] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Xia, Leiming
Tian, Wanlu
Zhao, Yiming
Jiang, Lingling
Qian, Wei
Jiang, Lei
Ge, Ling
Li, Jianjun
Jin, Fengbo
Yang, Mingzhen
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[4] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Leiming Xia
Wanlu Tian
Yiming Zhao
Lingling Jiang
Wei Qian
Lei Jiang
Ling Ge
Jianjun Li
Fengbo Jin
Mingzhen Yang
Signal Transduction and Targeted Therapy, 8
[5] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations
Pollyea, Daniel A.
Dinardo, Courtney D.
Arellano, Martha L.
Pigneux, Arnaud
Fiedler, Walter
Konopleva, Marina
Rizzieri, David A.
Smith, B. Douglas
Shinagawa, Atsushi
Lemoli, Roberto M.
Dail, Monique
Duan, Yinghui
Chyla, Brenda J.
Potluri, Jalaja
Ridgeway, Jean A.
Kantarjian, Hagop M.
BLOOD, 2020, 136
[6] A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
Manda, Sudhir
Anz III, Bertrand M.
Benton, Christopher
Broun, E. Randolph
Yimer, Habte A.
Renshaw, John S.
Geils Jr, George
Berdeja, Jesus
Cruz, Jose
Melear, Jason M.
Fanning, Suzanne
Fletcher, Luke
Li, Yukun
Duan, Yinghui
Werner, Michael E.
Potluri, Jalaja
Pai, Madhavi V.
Donnellan, William B.
HEMATOLOGICAL ONCOLOGY, 2024, 42 (03)
[7] Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
Konopleva, Marina
Thirman, Michael
Pratz, Keith W.
Letai, Anthony G.
Recher, Christian
Pullarkat, Vinod A.
Kantarjian, Hagop M.
Dail, Monique
Duan, Yinghui
Chyla, Brenda J.
Potluri, Jalaja
Miller, Catherine
Dinardo, Courtney D.
Wei, Andrew H.
BLOOD, 2020, 136
[8] Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia
Manda, Sudhir
Anz, Bertrand
Benton, Christopher
Broun, E. Randolph
Yimer, Habte
Renshaw, John
Geils, George F.
Cruz, Jose
Fanning, Suzanne
Melear, Jason
Sharman, Jeff P.
Kang, Kingston
Svensson, Anders
Pai, Madhavi
Donnellan, William
BLOOD, 2021, 138
[9] A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
DiNardo, Courtney
Pollyea, Daniel
Pratz, Keith
Thirman, Michael J.
Letai, Anthony
Frattini, Mark
Jonas, Brian
Leverson, Joel
Zhu, Ming
Dunbar, Martin
Falotico, Nancy
Kirby, Rachel
Agarwal, Suresh
Mabry, Mack
Potluri, Jalaja
Humerickhouse, Rod A.
Kantarjian, Hagop M.
Konopleva, Marina
BLOOD, 2015, 126 (23)
[10] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy (vol 52, pg 29, 2022)
Yamamoto, Kazuhito
Shinagawa, Atsushi
DiNardo, Courtney D.
Pratz, Keith W.
Ishizawa, Kenichi
Miyamoto, Toshihiro
Komatsu, Norio
Nakashima, Yasuhiro
Yoshida, Chikashi
Fukuhara, Noriko
Usuki, Kensuke
Yamauchi, Takahiro
Asada, Noboru
Asou, Norio
Choi, Ilseung
Miyazaki, Yasushi
Honda, Hideyuki
Okubo, Sumiko
Kurokawa, Misaki
Zhou, Ying
Zha, Jiuhong
Potluri, Jalaja
Matsumura, Itaru
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (05) : 456 - 456

← 1 2 3 4 5 →